VRTX
insider transactionsVERTEX PHARMACEUTICALS INC / MA — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-21.7K
0 buy · 21.7K sell
Net value · 90d
-$9.7M
$0 in · $9.7M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
11
0 buy · 21.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
EVP and CMO · 10b5-1
$1.8M
4.1K sh · $450.00
Own -19%
-
Sell·S
EVP and CMO · 10b5-1
$785.2K
1.7K sh · $450.00
Own -8%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$364.2K
828 sh · $439.91
Own -4%
-
Sell·S
EVP and CMO · 10b5-1
$888.3K
2.0K sh · $450.00
Own -8%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$15.0K
33 sh · $453.45
Own -0%
-
Sell·S
EVP and CMO · 10b5-1
$614.0K
1.4K sh · $453.45
Own -5%
-
Sell·S
EVP and CMO · 10b5-1
$3.1M
7.0K sh · $450.00
Own -21%
-
Sell·S
Director · 10b5-1
$134.7K
318 sh · $423.73
Own -6%
-
Grant·A
Director
—
796 sh
Own +28%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Other·D
Director
—
796 sh
Own -34%
-
Grant·A
Director
—
398 sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Other·D
Director
—
398 sh
Own -16%
-
Grant·A
Director
$0
472 sh
Own +23%
-
Grant·A
Director
—
796 sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Other·D
Director
—
796 sh
Own -36%
-
Grant·A
Director
$0
472 sh
Own +27%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$469.2K
1.1K sh · $425.02
Own -5%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Grant·A
Director
$0
472 sh
Own +7%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director · 10b5-1
$0
943 sh
Own +22%
-
Grant·A
Director
$35.6K
81 sh · $442.50
Own +3%
-
Grant·A
Director
$47.5K
107 sh · $442.50
Own +1%
-
Grant·A
Director
$15.0K
34 sh · $442.50
Own New
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$439.3K
978 sh · $449.17
Own -4%
-
Sell·S
EVP and CMO · 10b5-1
$1.1M
2.3K sh · $450.95
Own -7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Carmen Bozic 10b5-1 | Sell S | 4.1K | $1.8M |
| Jun 5, 2026 | Carmen Bozic 10b5-1 | Sell S | 1.7K | $785.2K |
| Jun 1, 2026 | Joy Liu 10b5-1 | Sell S | 828 | $364.2K |
| May 29, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.0K | $888.3K |
| May 15, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 33 | $15.0K |
| May 15, 2026 | Carmen Bozic 10b5-1 | Sell S | 1.4K | $614.0K |
| May 12, 2026 | Carmen Bozic 10b5-1 | Sell S | 7.0K | $3.1M |
| May 4, 2026 | Sangeeta N. Bhatia 10b5-1 | Sell S | 318 | $134.7K |
| May 1, 2026 | Suketu Upadhyay | Grant A | 796 | — |
| May 1, 2026 | Suketu Upadhyay | Grant A | 2.9K | $0 |
| May 1, 2026 | Suketu Upadhyay | Other D | 796 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 398 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 1.4K | $0 |
| May 1, 2026 | Nancy Thornberry | Other D | 398 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 472 | $0 |
| May 1, 2026 | Jennifer Schneider | Grant A | 796 | — |
| May 1, 2026 | Jennifer Schneider | Grant A | 1.4K | $0 |
| May 1, 2026 | Jennifer Schneider | Other D | 796 | — |
| May 1, 2026 | Jennifer Schneider | Grant A | 472 | $0 |
| May 1, 2026 | Bruce I Sachs | Grant A | 2.9K | $0 |
| May 1, 2026 | Joy Liu 10b5-1 | Sell S | 1.1K | $469.2K |
| May 1, 2026 | Michel Lagarde | Grant A | 2.9K | $0 |
| May 1, 2026 | Alan M Garber | Grant A | 1.4K | $0 |
| May 1, 2026 | Alan M Garber | Grant A | 472 | $0 |
| May 1, 2026 | Lloyd Carney | Grant A | 2.9K | $0 |
| May 1, 2026 | Sangeeta N. Bhatia 10b5-1 | Grant A | 943 | $0 |
| Apr 15, 2026 | Suketu Upadhyay | Grant A | 81 | $35.6K |
| Apr 15, 2026 | Bruce I Sachs | Grant A | 107 | $47.5K |
| Apr 15, 2026 | Alan M Garber | Grant A | 34 | $15.0K |
| Apr 1, 2026 | Joy Liu 10b5-1 | Sell S | 978 | $439.3K |
| Mar 27, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.3K | $1.1M |
About VRTX insider trading
This page tracks insider transactions for VERTEX PHARMACEUTICALS INC / MA (VRTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.